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Tuberculosis (TB) remains a major public health issue due to the increasing incidence 30 of type 2 diabetes mellitus (T2DM), which exacerbates the clinical course of TB and 31 increases the risk of poor long-term outcomes. The aim of this study was to 32 characterize the pharmacokinetics of rifampicin (RIF) and its relationship with TB and TB-T2DM   39 patients, who had high TNF-α and low IL-17 levels compared to healthy volunteers. 40 Delayed RIF absorption was observed in the TB and TB-T2DM patients; absorption 41 was poor and slower in the latter group due to poor glycemic control. RIF clearance 42 was also slower in the diabetic patients, thereby prolonging the mean residence time 43 of RIF. There was a significant association between the influence of diabetes, glycemic 44 control and increased TNF-α serum concentration and RIF pharmacokinetics in the 45 TB-T2DM patients. These altered metabolic and immune conditions may be factors in 46 anti-TB therapy management when TB and T2DM are concurrently present. 
56
The increasing incidence of type 2 diabetes mellitus (T2DM) raises the risk of 57 developing active TB in high-burden regions two-to eight-fold over the baseline, 58 especially in individuals with poor glycemic control (3-5). Moreover, an exacerbated 59 TB clinical course and an increased risk of poor long-term outcomes have been 60 reported for T2DM patients (6). 61 The cure rate reported after the directly observed treatment short-course (DOTS) for 62 TB was greater than 85%, with less than 5% of subjects relapsing (1). However, immunity, but their role in T2DM susceptibility to TB infection is unclear (7, 8 Previous studies involving patients with TB and T2DM reported significantly higher 325 levels of IFN-γ production in response to PPD than nondiabetic TB patients (15). 
